EA026588B1 - Составы на основе дарунавира - Google Patents

Составы на основе дарунавира Download PDF

Info

Publication number
EA026588B1
EA026588B1 EA201490223A EA201490223A EA026588B1 EA 026588 B1 EA026588 B1 EA 026588B1 EA 201490223 A EA201490223 A EA 201490223A EA 201490223 A EA201490223 A EA 201490223A EA 026588 B1 EA026588 B1 EA 026588B1
Authority
EA
Eurasian Patent Office
Prior art keywords
darunavir
dosage form
oral administration
hypromellose
mixture
Prior art date
Application number
EA201490223A
Other languages
English (en)
Russian (ru)
Other versions
EA201490223A1 (ru
Inventor
Юрбен Альфонс К. Делаэт
Филип Эрна Х. Хейнс
Эген Мария Йозеф Янс
Original Assignee
Янссен Сайенсиз Айрлэнд Юси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Сайенсиз Айрлэнд Юси filed Critical Янссен Сайенсиз Айрлэнд Юси
Publication of EA201490223A1 publication Critical patent/EA201490223A1/ru
Publication of EA026588B1 publication Critical patent/EA026588B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EA201490223A 2011-07-07 2012-07-06 Составы на основе дарунавира EA026588B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173066 2011-07-07
PCT/EP2012/063242 WO2013004816A1 (en) 2011-07-07 2012-07-06 Darunavir formulations

Publications (2)

Publication Number Publication Date
EA201490223A1 EA201490223A1 (ru) 2014-06-30
EA026588B1 true EA026588B1 (ru) 2017-04-28

Family

ID=46458539

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490223A EA026588B1 (ru) 2011-07-07 2012-07-06 Составы на основе дарунавира

Country Status (23)

Country Link
US (3) US20140142174A1 (enExample)
EP (1) EP2729128B1 (enExample)
JP (1) JP6101260B2 (enExample)
KR (1) KR101817991B1 (enExample)
CN (1) CN103841962B (enExample)
AU (1) AU2012280277B2 (enExample)
BR (1) BR112014000195A2 (enExample)
CA (1) CA2837539C (enExample)
CY (1) CY1119446T1 (enExample)
DK (1) DK2729128T3 (enExample)
EA (1) EA026588B1 (enExample)
ES (1) ES2598823T3 (enExample)
HR (1) HRP20161340T1 (enExample)
HU (1) HUE030341T2 (enExample)
IL (1) IL229700B (enExample)
LT (1) LT2729128T (enExample)
MX (1) MX341976B (enExample)
PL (1) PL2729128T3 (enExample)
PT (1) PT2729128T (enExample)
RS (1) RS55236B1 (enExample)
SI (1) SI2729128T1 (enExample)
SM (1) SMT201600380B (enExample)
WO (1) WO2013004816A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨,替诺福韦,达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
EP3210017B1 (en) 2014-10-26 2021-10-06 King Abdullah University Of Science And Technology Alkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (hiv)
MX2020000694A (es) 2017-07-20 2020-07-29 Janssen Sciences Ireland Unlimited Co Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
US20200101093A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
WO2021216475A1 (en) * 2020-04-20 2021-10-28 Poviva Corp. Compositions and methods for enhanced delivery of antiviral agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000853A2 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Ltd. Combination formulations comprising darunavir and etravirine
WO2009013356A2 (en) * 2007-07-25 2009-01-29 Tibotec Pharmaceuticals Ltd. Anti-hiv tablet formulations comprising darunavir
WO2009081174A2 (en) * 2007-12-24 2009-07-02 Cipla Limited Anti - retroviral combination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2127938T3 (es) 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
AR037797A1 (es) 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
CA2776807C (en) * 2009-09-17 2018-10-16 Mylan Laboratories Limited An improved process for the preparation of darunavir

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000853A2 (en) * 2007-06-25 2008-12-31 Tibotec Pharmaceuticals Ltd. Combination formulations comprising darunavir and etravirine
WO2009013356A2 (en) * 2007-07-25 2009-01-29 Tibotec Pharmaceuticals Ltd. Anti-hiv tablet formulations comprising darunavir
WO2009081174A2 (en) * 2007-12-24 2009-07-02 Cipla Limited Anti - retroviral combination

Also Published As

Publication number Publication date
DK2729128T3 (en) 2016-11-21
CA2837539A1 (en) 2013-01-10
EP2729128B1 (en) 2016-07-27
US20160113949A1 (en) 2016-04-28
CY1119446T1 (el) 2018-04-04
HRP20161340T1 (hr) 2016-12-02
EA201490223A1 (ru) 2014-06-30
MX2013015196A (es) 2014-08-18
AU2012280277A1 (en) 2013-12-19
PL2729128T3 (pl) 2017-05-31
IL229700B (en) 2018-04-30
SMT201600380B (it) 2017-01-10
CN103841962B (zh) 2016-08-17
MX341976B (es) 2016-09-07
RS55236B1 (sr) 2017-02-28
IL229700A0 (en) 2014-01-30
LT2729128T (lt) 2016-11-10
JP2014520786A (ja) 2014-08-25
KR101817991B1 (ko) 2018-01-12
HUE030341T2 (en) 2017-05-29
JP6101260B2 (ja) 2017-03-22
CN103841962A (zh) 2014-06-04
BR112014000195A2 (pt) 2017-02-21
AU2012280277B2 (en) 2017-02-09
EP2729128A1 (en) 2014-05-14
US20140142174A1 (en) 2014-05-22
PT2729128T (pt) 2016-09-21
KR20140068844A (ko) 2014-06-09
WO2013004816A1 (en) 2013-01-10
CA2837539C (en) 2021-08-10
US20210244749A1 (en) 2021-08-12
ES2598823T3 (es) 2017-01-30
SI2729128T1 (sl) 2016-11-30

Similar Documents

Publication Publication Date Title
US11654150B2 (en) Darunavir combination formulations
JP6101260B2 (ja) ダルナビル製剤
EP2854773B1 (en) Pharmaceutical composition of entecavir and process of manufacturing
CN113616606A (zh) 帕博西尼的固体剂型
EP3345626A1 (en) Super-rapid disintegrating tablet, and method for producing same
WO2015140709A1 (en) Solid pharmaceutical dosage forms